Prof. Adnan Erol’s preprints present early-stage scientific hypotheses and mechanistic perspectives across COVID-19 immunopathology, metabolic inflammation, cellular signaling, and neurodegeneration.
Preprint notice: These manuscripts were shared before formal peer review. They are provided for scholarly discussion and should not be interpreted as clinical recommendations. COVID-19-related manuscripts reflect the evidence and hypotheses available at the time of writing.
TNFR2–NIK–c-Abl Axis for Neurodegeneration
PREPRINT · 2023
This work examines how dysregulated TNFR2, NIK, and c-Abl signaling may contribute to chronic inflammation, mitochondrial dysfunction, and neurodegenerative disease.
Defective Efferocytosis as a Predictor of COVID-19 Mortality
PREPRINT · 2021
An exploration of defective efferocytosis—the impaired clearance of dying cells—as a possible mechanism linking chronic disease, uncontrolled inflammation, and mortality risk in COVID-19.
Later peer-reviewed publication:
Importance of Efferocytosis in COVID-19 Mortality →
Possible Long-Term Downsides of Antibodies Caused by the COVID-19 Vaccine
PREPRINT · 2021
A theoretical discussion of possible long-term biological effects associated with vaccine-induced antibodies, written during the early stages of worldwide COVID-19 vaccination.
Are the Emerging SARS-CoV-2 Mutations Friend or Foe?
PREPRINT · 2020
This manuscript examines emerging SARS-CoV-2 variants, including D614G and N501Y, and considers how viral mutations may influence transmissibility, immunogenicity, and vulnerability to immune responses.
Later peer-reviewed publication:
View in Immunology Letters via PubMed →
Pioglitazone Treatment for the COVID-19-Associated Cytokine Storm
PREPRINT · 2020
A mechanistic hypothesis proposing that the anti-inflammatory and insulin-sensitizing effects of pioglitazone may help regulate the excessive immune response associated with severe COVID-19.
High-Dose Intravenous Vitamin C Treatment for COVID-19
PREPRINT · 2020
A mechanistic discussion of high-dose intravenous vitamin C as a potential early intervention for excessive immune activation and inflammatory lung injury in hospitalized COVID-19 patients.
Explore More Research
Complete publication records and additional scholarly work are available through: